Study of two drugs for metastatic triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, naxitamab and sacituzumab govitecan, for people with metastatic triple-negative breast cancer that has already been treated with at least one chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have metastatic triple-negative breast cancer that has gotten worse after at least one chemotherapy treatment
- You are able to provide a sample of your tumor tissue from a previous biopsy or surgery
- You have not had severe side effects from naxitamab or sacituzumab govitecan before
- You do not have uncontrolled high blood pressure, serious heart or lung disease, or active infections
- You have not had radiation therapy within the last week before starting the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three drugs—sacituzumab govitecan, nivolumab, and relatlimab—for people with metastatic triple-negative breast cancer that has progressed after at least one prior therapy. You may qualify if you have this specific type of breast cancer and have received certain prior treatments.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted therapy) and Q901 (a study drug that blocks a protein needed for cancer cell growth)—in people with advanced triple-negative breast cancer who have already tried other treatments. The goal is to see if this combination can shrink or control the cancer.
This trial is studying how patients with metastatic triple-negative breast cancer feel and function during treatment with sacituzumab govitecan (a targeted therapy) or standard chemotherapy, using patient-reported outcomes. It aims to better understand the real-world effectiveness and impact on quality of life in Chinese patients.
This study is testing a drug called sacituzumab govitecan (SG) for people with advanced triple-negative breast cancer who have already had other treatments. The goal is to see how well the drug works and what side effects it causes, using your tumor samples to look for clues (biomarkers).
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
This trial compares two antibody-drug conjugates (targeted cancer-killing drugs) given one after the other to see if they work well for triple-negative breast cancer with low HER2. It aims to provide a new treatment option that may slow the cancer's growth.
Hear when a new Metastatic Triple-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.